CBIS - CBIS Stock Down 4%: New Member Joins Scientific Advisory Board

While other cannabis companies focus on acquisitions and entering different markets, Cannabis Science (OTCPK:CBIS) continues to develop its clinical trial teams. Earlier today, the US company announced that it has appointed an influential member of the medical field to lead its cancer clinical trial. CBIS stock, however, didn’t jump on the news; it is down around 4%.

Based in Irvine, California, Cannabis Science specializes in the development of CBD-based medicines. In the remainder of 2019, Cannabis Science will conduct various clinical trials; it will be looking at everything from lung cancer and ...